EP Patent

EP4667005A2 — Combination therapies for the treatment of hepatocellular carcinoma

Assigned to Eisai R&D Management Co Ltd · Expires 2025-12-24 · 0y expired

What this patent protects

Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.

USPTO Abstract

Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: EP4667005A2
Jurisdiction: EP
Classification: —
Expires: 2025-12-24
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.